SCHEMBL31401432

SCHEMBL31401432

CC(C)(C)OC(=O)NCc1cc2cc(Cl)ccc2cn1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.42
KDM4A O75164 1/20 0.42
IDO1 P14902 2/20 0.42
STK17B O94768 1/20 0.41
STK17A Q9UEE5 1/20 0.41
MAPKAPK2 P49137 2/20 0.40
DYRK1A Q13627 2/20 0.40
GSK3B P49841 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
TRPA1 O75762 1/20 0.40
BRD4 O60885 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 1/20 0.39
ANO1 Q5XXA6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26143885 0.85 KDM4A (0.42) KDM4ADYRK1AGSK3BL3MBTL1
SCHEMBL30097062 0.85 KDM4A (0.42) KDM4ADYRK1AGSK3BL3MBTL1
SCHEMBL3633138 0.85 KDM4A (0.54) KDM4ADYRK1AL3MBTL1
SCHEMBL23705506 0.83 KDM4A (0.42) GAAKDM4ASTK17BSTK17AMAPKAPK2
SCHEMBL29673310 0.83 KDM4A (0.42) GAAKDM4ASTK17BSTK17AMAPKAPK2
SCHEMBL29673308 0.83 KDM4A (0.42) GAAKDM4ASTK17BSTK17AMAPKAPK2
SCHEMBL22828360 0.82 TRPA1 (0.50) GAAKDM4AIDO1STK17BSTK17A
SCHEMBL30097039 0.81 NAMPT (0.45) KDM4ASTK17BSTK17ADYRK1AL3MBTL1
SCHEMBL26143921 0.81 NAMPT (0.45) KDM4ASTK17BSTK17ADYRK1AL3MBTL1
SCHEMBL10547182 0.81 ATR (0.46) GAAKDM4AIDO1STK17BSTK17A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739682-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS Janssen Pharmaceutica NV (BE) 2026-05-13 EP disclosed
WO-2025008058-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS JANSSEN PHARMACEUTICA NV (BE) 2025-01-09 WO disclosed